Taro Pharmaceutical Industries Ltd.
TARO
TARO was delisted on the 21st of June, 2024.
82 hedge funds and large institutions have $704M invested in Taro Pharmaceutical Industries Ltd. in 2014 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 28 increasing their positions, 24 reducing their positions, and 12 closing their positions.
75% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 12
29% more funds holding in top 10
Funds holding in top 10: 7 → 9 (+2)
17% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 24
12% more funds holding
Funds holding: 73 → 82 (+9)
6% more capital invested
Capital invested by funds: $665M → $704M (+$38.7M)
80% less call options, than puts
Call options by funds: $308K | Put options by funds: $1.54M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$9.19M |
| 2 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
+$7.48M |
| 3 |
Millennium Management
New York
|
+$6.91M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$6.39M |
| 5 |
RFC
Russell Frank Company
Seattle,
Washington
|
+$6.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
-$35.5M |
| 2 |
PA
Perceptive Advisors
New York
|
-$24.1M |
| 3 |
RCM
Raging Capital Management
Rocky Hill,
New Jersey
|
-$11.5M |
| 4 |
CCM
Consonance Capital Management
New York
|
-$10.1M |
| 5 |
MCP
Moab Capital Partners
Southampton,
New York
|
-$4.47M |
TARO Hedge Fund Activity: Q3 2014 in Review
82 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Taro Pharmaceutical Industries Ltd. (TARO) for Q3 2014, worth a combined $704M — up 5.8% from $665M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new TARO positions and 12 closed out — a net gain of 9 holders — while 28 added to existing stakes and 24 trimmed.
The largest buyer was Acadian Asset Management, adding an estimated $9.19M. The largest seller was Hotchkis & Wiley Capital Management, cutting an estimated $35.5M.
- 82 institutional investors held Taro Pharmaceutical Industries Ltd. (TARO) as of Q3 2014, up from 73 in Q2 2014.
- Funds reported $704M of Taro Pharmaceutical Industries Ltd. stock for Q3 2014, up 5.8% quarter-over-quarter.
- 21 funds opened new Taro Pharmaceutical Industries Ltd. positions in Q3 2014 and 12 closed out, a net change of +9 holders.
- The largest Taro Pharmaceutical Industries Ltd. buyer in Q3 2014 was Acadian Asset Management, an estimated $9.19M added.
- The largest Taro Pharmaceutical Industries Ltd. seller in Q3 2014 was Hotchkis & Wiley Capital Management, an estimated $35.5M sold.
Based on aggregated 13F filings for Q3 2014.